ArticleBMC cancer2012
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.
Article in BMC cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Vascular Toxicities of Cancer Therapies: 2025 Update.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Sorafenib-to-regorafenib sequence-induced atherosclerotic cardiovascular disease: a novel case report.Frontiers in oncology · 2025Article
- Mechanism of action and experimental validation of key genes common to diabetic retinopathy and coronary heart disease based on multiple bioinformatics investigations.Frontiers in genetics · 2025Article
- Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review.Frontiers in medicine · 2024Review
- Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics.Diseases (Basel, Switzerland) · 2023Article
- Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma.Biomedicines · 2023Review
- Antithrombotic strategy in cancer patients comorbid with acute coronary syndrome and atrial fibrillation.Frontiers in cardiovascular medicine · 2023Review
- Cardiotoxic effects of angiogenesis inhibitors.Clinical science (London, England : 1979) · 2021Review
- Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer.Journal of clinical medicine · 2020Review
- Management of Patients with Acute Coronary Syndrome and Cancer.Current cardiology reports · 2020Review
- Optimal management of coronary artery disease in cancer patients.Chronic diseases and translational medicine · 2019Review
- Common Vascular Toxicities of Cancer Therapies.Cardiology clinics · 2019Review
- Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer.Haematologica · 2018Article
- Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events.Journal of the American Society of Hypertension : JASH · 2018Review
- Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.Molecular and clinical oncology · 2017Article
- Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.Journal of gastrointestinal oncology · 2016Article
- Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System?Current oncology reports · 2016Review
- Predictors of incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors.Journal of clinical ultrasound : JCU · 2016Article
- Review
- Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.BMC urology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTyrosine kinase inhibitors (TKIs) are currently approved for the treatment of metastatic renal cell carcinoma (mRCC). The cardiotoxic effects of sorafenib and sunitinib may cause hypertension, left ventricular ejection fraction (LVEF) dysfunction and/or congestive heart failure (CHF), and arterial thrombo-embolic events (ATE). Only three cases of coronary artery disease related to sorafenib therapy have been described in the literature, and all were due to arterial vasospasm without evidence of coronary artery stenosis on angiography. Cardiotoxicity is commonly associated with the presence of cardiovascular risk factors, such as a history of hypertension or coronary artery disease. CASE PRESENTATION: We describe a patient who experienced an unusual cardiac event after 2 years of sorafenib treatment. A 58-year-old man with mRCC developed acute coronary syndrome (ischemia/infarction) associated with critical sub-occlusion of the common trunk of the left coronary artery and some of its branches, which was documented on coronary angiography. The patient underwent triple coronary artery bypass surgery, and sorafenib treatment was discontinued. He did not have any cardiovascular risk factors, and his cardiac function and morphology were normal prior to sorafenib treatment.
conclusionsFurther investigation of a larger patient population is needed to better understand cardiac damage due to TKI treatment. Understanding the usefulness of careful cardiovascular monitoring might be important for the prevention of fatal cardiovascular events, and to avoid discontinuation of therapy for the underlying cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.